Patent · US Active

Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

US9382255B2 · kind B2 · utility

3Cited by

4References

9Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Ulrich Klar · Berlin, DE
Lars Wortmann · Berlin, DE
Georg Kettschau · Berlin, DE
Florian Puehler · Wellesley, US
Philip Lienau · Berlin, DE
Kirstin Petersen · Berlin, DE
Andrea Hägebarth · Berlin, DE
Detlev Sülzle · Berlin, DE
Anja Richter · Berlin, DE

Key dates

Filing date	Sep 18, 2013
Grant date	Jul 5, 2016
Priority date	—
Expiry date	Sep 18, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D473/34
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.